Skip to main content

Xoma to Supply Antibody Agents to SRI International for NIAID Study

NEW YORK (GenomeWeb News) — Xoma today said it will create monoclonal antibody agents for SRI International as part of that company’s deal with the National Institute of Allergy and Infectious Disease.
 
Xoma said the firms are still negotiating their contract, which will span 5 years and could be worth as much as $28.1 million. The company added that, if the full contract is awarded it will bring to $60 million the total amount of government contracts it has received since 2005.
 
Additional details were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.